Literature DB >> 6127096

Azo reduction of sulphasalazine in healthy volunteers.

J B Houston, J Day, J Walker.   

Abstract

1 A comparison of total sulphapyridine saliva concentrations resulting from administration of sulphapyridine and sulphasalazine at equimolar doses has been carried out. It is concluded that the extent of azo reduction of sulphasalazine to release sulphapyridine is complete in healthy volunteers. 2 An ampicillin course of treatment alters the azo reduction of sulphasalazine. The extent of cleavage is reduced by one third on average. There is no change in the rate of absorption of the release sulphapyridine. 3 An ampicillin course of treatment does not alter the disposition of sulphapyridine. The changes noted in acetyl conjugate plasma concentrations are entirely consistent with reduced availability of sulphapyridine.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6127096      PMCID: PMC1427633          DOI: 10.1111/j.1365-2125.1982.tb01997.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine.

Authors:  T R Bates; H P Blumenthal; H J Pieniaszek
Journal:  Clin Pharmacol Ther       Date:  1977-12       Impact factor: 6.875

2.  The role of intestinal bacteria in the metabolism of salicylazosulfapyridine.

Authors:  M A Peppercorn; P Goldman
Journal:  J Pharmacol Exp Ther       Date:  1972-06       Impact factor: 4.030

3.  Absorption, metabolism, and excretion of salicylazosulfapyridine in man.

Authors:  H Schröder; D E Campbell
Journal:  Clin Pharmacol Ther       Date:  1972 Jul-Aug       Impact factor: 6.875

4.  Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.

Authors:  J M Day; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1980-01       Impact factor: 4.335

5.  Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine.

Authors:  K A Hansson; M Sandberg
Journal:  Acta Pharm Suec       Date:  1973-03

6.  National Cooperative Crohn's Disease Study: results of drug treatment.

Authors:  R W Summers; D M Switz; J T Sessions; J M Becktel; W R Best; F Kern; J W Singleton
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

Review 7.  Clinical pharmacokinetics of sulphasalazine.

Authors:  K M Das; R Dubin
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

8.  A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

Authors:  A S Dissanayake; S C Truelove
Journal:  Gut       Date:  1973-12       Impact factor: 23.059

9.  Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

Authors:  A K Azad Khan; D T Howes; J Piris; S C Truelove
Journal:  Gut       Date:  1980-03       Impact factor: 23.059

10.  An experiment to determine the active therapeutic moiety of sulphasalazine.

Authors:  A K Azad Khan; J Piris; S C Truelove
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

View more
  11 in total

1.  Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP.

Authors:  Hiroyuki Kusuhara; Hidetoshi Furuie; Akihiro Inano; Akihiro Sunagawa; Saiko Yamada; Chunyong Wu; Shinya Fukizawa; Nozomi Morimoto; Ichiro Ieiri; Mariko Morishita; Kiminobu Sumita; Hiroshi Mayahara; Takuya Fujita; Kazuya Maeda; Yuichi Sugiyama
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

3.  Why do patients with ulcerative colitis relapse?

Authors:  S A Riley; V Mani; M J Goodman; S Lucas
Journal:  Gut       Date:  1990-02       Impact factor: 23.059

4.  The effect of rifampicin on sulphapyridine plasma concentrations following sulphasalazine administration.

Authors:  J L Shaffer; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

5.  Disposition of metronidazole and its effects on sulphasalazine metabolism in patients with inflammatory bowel disease.

Authors:  J L Shaffer; A Kershaw; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

6.  Controlled trial of rifampicin and ethambutol in Crohn's disease.

Authors:  J L Shaffer; S Hughes; B D Linaker; R D Baker; L A Turnberg
Journal:  Gut       Date:  1984-02       Impact factor: 23.059

Review 7.  Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

Review 8.  Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes.

Authors:  Nielsen Q Fernandez-Becker; Alan C Moss
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects.

Authors:  S A Riley; I A Tavares; A Bennett; V Mani
Journal:  Br J Clin Pharmacol       Date:  1988-08       Impact factor: 4.335

10.  RNA-Seq Quantification of Hepatic Drug Processing Genes in Germ-Free Mice.

Authors:  Felcy Pavithra Selwyn; Julia Yue Cui; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2015-05-08       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.